CH

Charmtx

4 known investors

charmtx.com ↗

CHARM is a biotech company developing a next-generation menin inhibitor for acute myeloid leukemia (AML), designed to address resistance seen with first-generation approaches. It applies AI and structure-based drug discovery to design potent inhibitors targeting protein-ligand interactions at the KMT2A interface on menin.

Investors · 4

F-

F-Prime Capital PartnersCambridge · $3M – $10M

OR

OrbiMedNew York · $1M – $75M

AX

Axial VCreportedSan Francisco · $100K – $5M

NV

NVenturesreportedSanta Clara